Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues

Abstract

Objective:To analyze the clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.Methods:One hundred and eight tissue samples from the patients with endometrial cancer enrolled in our hospital from August 2011 to July 2014 were selected, including 60 normal tissue samples (normal group), 60 neoplastic tissue samples (neoplastic group) and 60 cancer tissue samples (cancer group). All the samples were subjected to immunohistochemical assay to detect the expressions of COX-2, GLUT-1 and VEGF. The clinical data were also investigated for correlation analysis.Results:The positive rates of COX-2 in normal group, neoplastic group and cancer groups were 3.3%, 21.7% and 55.0% respectively. The positive rates of GLUT-1 in normal group, neoplastic group and cancer groups were 3.3%, 25.0% and 70.0% respectively. The positive rates of VEGF in normal group, neoplastic group and cancer groups were 1.7%, 23.3% and 63.3% respectively. With increasing stage of such cancer, decreasing degree of differentiation and lymphatic metastasis, the positive expression rates of COX-2, GLUT-1 and VEGF proteins were raised significantly (P<0.05). Spearman’s correlation analysis showed that the expressions of COX-2 and GLUT-1 (r=0.207, P<0.05), COX-2 and VEGF (r=0.243, P<0.05), as well as GLUT-1 and VEGF (r=0.758, P<0.05) were positively correlated.Conclusion:COX-2, GLUT-1 and VEGF were highly prominent in endometrial cancer, especially in the patients with low degree of differentiation, late stage and metastasis. They functioned synergistically in the onset and progression of this cancer.

Glut-1 expression in proliferative endometrium, endometrial hyperplasia, endometrial adenocarcinoma and the relationship between glut-1 expression and prognostic parameters in endometrial adenocarcinoma

“…In 2010 Xiong et al (19) similarly failed to show a correlation between the prognostic parameters and GLUT-1 expression in endometrioid adenocarcinoma. In accordance with the literature data, our results suggest that GLUT-1 is a marker of early stages of endometrial neoplastic transformation (17)(18)(19)35,37).…”

“…In endometrial tumors, on the other hand, the correlation between GLUT-1 expression and clinical characteristics, i.e. increasing stage, decreasing degree of differentiation, and lymphatic metastasis, was significant (P<0.05) (35). Among ETEA's prognostic parameters, grade was found to be significantly correlated to GLUT-1 expression in our study.…”

“…This distinction would be guiding to detect EH with atypia, which is a strong risk factor for endometrial carcinoma that is known to play an important role in the genesis of endometrial tumors, especially Type 1. GLUT-1 is highly expressed in endometrial cancer, which can be used to differentiate benign endometrium from atypically hyperplastic endometrium (17)(18)(19)35). Since increased expression of GLUT-1 is already known in many neoplasms, its relationship with prognostic parameters has been studied.…”

Immunohistochemical Expression of Glut-1 in Epithelial Ovarian Tumors: Correlation With the Clinicopathological Factors and Tumor Proliferative Marker Pcna.

“…However, in contrast to our finding, Iida et al [35], reportedGlut-1 expression in 68% of benign tumors, 95% of borderline and in all cases of ovarian carcinomas (100%). These differences in the finding may be due to differences in the cohort number (Iida: 102 ovarian tumors, ours: 45), different staining technique, the use of different primary antibody types and the use of different methods of evaluation of marker immunoreactivity.…”

GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma

“…Many recent studies associated GLUT1 expression with increased malignant potential, invasiveness, diagnosis, prognosis and survival in different neoplasms, including prostate, breast, colorectal, ovarian, lung, hepatic, pancreatic, esophageal and cervical carcinomas [8][9][10]. However, in endometrial cancer, many studies attempted to find similar association and prove that GLUT1 phenotype could be utilized as a diagnostic and prognostic tissue marker, but the findings were inconsistent and need further confirmation [11][12][13][14][15][16][17][18][19][20][21][22]. Therefore, this manuscript will describe the immunohistochemistry phenotype of GLUT1 in a panel of endometrial carcinomas compared to normal tissues, and analyse its relationship with clinicopathological features, to determine its clinical value and its role in endometrial cancer.…”